Remdesivir for Patients with COVID-19 (Adults and Adolescents 12 years and older) Guidelines for NHS GGC (1021)
Warning
exp date isn't null, but text field is
Abstract
Remdesivir is an adenosine nucleotide prodrug that is metabolised intracellularly to form the pharmacologically active substrate remdesivir triphosphate. Remdesivir triphosphate inhibits SARS-CoV-2 RNA polymerase which perturbs viral replication.
Current evidence shows that remdesivir improves clinical outcomes in both hospitalised and non-hospitalised patients with COVID-19.